Contineum Therapeutics Narrows Q1 Net Loss to $(14.5)M, Reports Strong $246M Cash Position
summarizeSummary
Contineum Therapeutics reported a first-quarter 2026 net loss of $(14.5)M, or $(0.39) per diluted share, an improvement from a $(16.0)M loss in the year-ago quarter. The company also disclosed a robust cash and marketable securities balance of approximately $246M as of March 31, 2026. This financial update follows the recent positive topline Phase 1b data for its chronic pain drug candidate, PIPE-791, announced on April 30, 2026. The reduced net loss and significant cash reserves, expected to fund operations for at least 12 months, provide crucial financial stability for this clinical-stage biotech to advance its pipeline. Investors will continue to monitor the progress of ongoing clinical trials, particularly the PIPE-791 Phase 2 study, for future catalysts.
At the time of this announcement, CTNM was trading at $14.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $557.7M. The 52-week trading range was $3.35 to $16.33. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.